drugset / Trial / NCT04363164
Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression
Phase 2
Recruiting
150 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
United States Department of Defense · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Asymptomatic men without pain due to prostate cancer progressing with metastatic CRPC after treatment with combination or sequential ADT + Abi will be treated on a randomized, open label study to determine if sequential treatment with high dose T and Enza will improve primary and secondary objectives vs. continuous Enza as standard therapy.
Timeline
- Start
- 2020-08-19
- Primary completion
- 2027-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | Testosterone Cypionate | Small molecule | 400 mg | Intramuscular |
| Subject | Testosterone Enanthate | Small molecule | — | Intramuscular |